Biotechnology

Viewpoint Molecular Targeting(R) Appoints Ewa Matczak MD, as Chief Medical Officer

June 30, 2021 10:00 AM

Medical oncologist specializing in hematology/oncology with 10 years of clinical and translational medicine research and 20 years of experience in early- and late-stage drug development at multiple leading global pharmaceutical companies CORALVILLE, IA / ACCESSWIRE / June 30, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology...

Read more

International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease

June 30, 2021 8:57 AM

CARLSBAD, CA / ACCESSWIRE / June 30, 2021 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today successful completion of its dose escalating phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT02452723) evaluating the safety, tolerability and...

Read more

Applied UV Continues International Expansion with Airocide(R) Installation in Swiss International School

June 30, 2021 8:30 AM

Airocide® technology helps schools reopen and allow for the safe return to campus Distributor installation will serve as a prototype project for the expansion of the Airocide® solution into the school systems located in the EU MOUNT VERNON, NY / ACCESSWIRE / June 30, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for...

Read more

Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase

June 30, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 agonists and antagonists coupled with the proprietary drug delivery systems in the treatment of various disorders including human pancreatic cancer and colon cancer. The work the Company is contracting to conduct is intended to do pre-clinical...

Read more

Lexaria Announces 2021 Annual Meeting Results

June 29, 2021 4:05 PM

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On June 28, 2021 at 1:00 p.m. (Pacific Time), the Company held the Meeting whereby there were 2,735,413 shares of the Company represented in person or by proxy at the meeting, constituting 53.6% of the...

Read more

Wuhan Sciences Launches the M2Bio Surfboard NFT Collection

June 29, 2021 9:20 AM

CAPE TOWN, SA / ACCESSWIRE / June 29, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: M2Bio Sciences is stepping into the realm of non-fungible tokens (NFTs) with their first NFT auction featuring 10 psychedelic M2Bio Surfboards. The artwork is inspired by their efforts of...

Read more

Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101

June 29, 2021 7:00 AM

- Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with Agents Targeting TLRs 2 and 4 or TLR 7 Alone - NOVATO, CA / ACCESSWIRE / June 29, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on immunotherapies to treat and prevent...

Read more

Applied UV Announces Offering of Preferred Stock

June 28, 2021 8:00 AM

Proceeds to be used for general corporate purposes, including new investments and potential future acquisitions MOUNT VERNON, NY / ACCESSWIRE / June 28, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly,...

Read more

Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting

June 28, 2021 7:00 AM

NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on immunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, announced today that it has submitted its initial application to list the company's common stock on the Nasdaq Capital Market. The listing of Mosaic's shares on...

Read more

Biopharmaceutical Company Lands Feature in Popular Industry Publication With the Help of Newswire

June 25, 2021 10:15 AM

NEW YORK, NY / ACCESSWIRE / June 25, 2021 / A major component of a media and marketing communications strategy is securing valuable earned media opportunities to build brand awareness and connect with a company's target audience. At the end of March, Newswire was able to do just that for one of its Media and Marketing Guided Tour clients in the biopharmaceutical space by securing a feature story in a prominent industry publication. This feature...

Read more

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

June 25, 2021 7:00 AM

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant to enable the evaluation of PRS-220 for the treatment of post-COVID-19-related pulmonary fibrosis for clinical-readiness in general and initial clinical development of PRS-220 in the post-COVID-19 setting Clinical development of PRS-220 expected to...

Read more

Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants

June 24, 2021 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / June 24, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has appointed Marcum LLP as the Company's new auditor, replacing BDO Canada LLP. The Company has filed a Notice of Change of Auditor in respect of this change under its SEDAR profile at www.sedar.com. The...

Read more

Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

June 24, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, for the treatment of...

Read more

Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment

June 23, 2021 7:55 AM

TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of a key member to its management team to support the company's expanding manufacturing activities. Rajan Puri has been appointed to the newly established position of Senior Vice President of Manufacturing. Mr. Puri is an expert in Chemistry,...

Read more

Pressure BioSciences to Present at the Emerging Growth Conference

June 22, 2021 7:47 AM

Company Invites Individual and Institutional Investors, as well as Analysts and Advisors, to Attend Its Real-Time, Interactive Presentation on Wednesday, June 23, 2021 SOUTH EASTON, MA / ACCESSWIRE / June 22, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences,...

Read more

Gary Herman Joins GB Sciences' Subsidiary GbS Global Biopharma as Advisory Director

June 22, 2021 7:00 AM

LAS VEGAS / ACCESSWIRE / June 22, 2021 / GB Sciences, Inc. (OTCQB:GBLX) announces that long-term investor Gary Herman has joined GbS Global Biopharma, Inc., its wholly owned Canadian subsidiary, as an Advisory Director. Herman has a strong investment background in growth companies in the cannabis, biopharma, and technology sectors. An experienced fund manager and investor who sits on several corporate boards, Herman brings over 20 years of...

Read more

Applied UV and FSG Sign Master Distributor Agreement

June 21, 2021 1:50 PM

MOUNT VERNON, NY / ACCESSWIRE / June 21, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced the signing of a Master Distributor agreement for the United States with FSG,...

Read more

Applied UV Receives Initial Purchase Orders in Excess of $850,000 from 3Sixty Biopharmaceuticals, its Exclusive Distributor for Airocide(R) Air Purification Systems for the Continent of Africa

June 18, 2021 8:30 AM

Initial order is part of $3.5 million minimum first year purchase commitment of Airocide® systems MOUNT VERNON, NY / ACCESSWIRE / June 18, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and...

Read more

Edesa Biotech Reports Favorable Review of COVID-19 Study

June 18, 2021 7:45 AM

TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an independent Data and Safety Monitoring Board (DSMB) has completed an interim review of the company's COVID-19 drug candidate, and based on blinded comparative data, has recommended that the company's international study continue as planned. The safety...

Read more

Applied UV Announces Laboratory Results Confirm SteriLumen's Lumicide(TM) Ribbon Kills SARS-CoV-2 (COVID-19 Virus)

June 16, 2021 8:30 AM

Previously reported independent lab results confirmed killing OC43 human coronavirus ("OC43"), a common surrogate for SARS-CoV-2, the virus that causes COVID-19 MOUNT VERNON, NY / ACCESSWIRE / June 16, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air...

Read more